ALK ALK FUSION G1202R

alk融合与alk激酶域的g1202r突变在肺腺癌患者中首次被发现，该患者在对环唑替尼治疗10个月后进展。该变异体的进一步鉴定证实了环唑替尼的耐药性，并进一步证明了对多种新一代alk抑制剂的耐药性，包括西替尼、阿来替尼和布赖卡汀尼。使用hsp90抑制剂17-aag进行的实验表明，eml4-alk g1202r对该药物具有潜在的敏感性，表明该变异体可能是hsp90客户蛋白。
ALK fusion with G1202R mutation in the ALK kinase domain was first identified in a lung adenocarcinoma patient who had progressed after 10 months of responding to crizotinib. Further characterization of this variant verified crizotinib resistance and additionally demonstrated resistance to multiple next generation ALK inhibitors including ceritinib, alectinib and brigatinib. Experiments using the HSP90 inhibitor 17-AAG have indicated potential sensitivity of EML4-ALK G1202R to this drug, suggesting this variant may be an HSP90 client protein.